Company Filing History:

6 out of 6,662

Hoechst Aktiengesellschaft

patents

4 out of 1,187

The Scripps Research Institute

patents

2 out of 330

Aventis Pharma Deutschland, Gmbh

where one patent can have more than one assignee

Years Active: 1994-2001

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6221844 - Antifungal peptides from scleroderma texense (2001-04-24),

2. 6174722 - In-vitro transcription processes for screening natural products and other chemical substances (2001-01-16),

3. 6037467 - Methods for preparing carbohydrate-containing hydrophilic polymers (2000-03-14),

4. 5994307 - Methods of treatment with novel antibiotic feglymycin (1999-11-30),

5. 5939399 - Polyene antibiotics, 3874 H1 to H6, processes for their preparation and (1999-08-17),

6. 5891851 - Antibiotic, feglymycin, processes for its preparation and its use (1999-04-06),

7. 5707979 - Phosphinic acid derivatives, their preparation and their use (1998-01-13),

8. 5639797 - Water-in-oil emulsions containing water-soluble alkyl glycosides (1997-06-17),

9. 5527805 - Dynemicin analogs: syntheses, methods of preparation and use (1996-06-18),

10. 5470843 - Carbohydrate-containing polymers, their preparation and use (1995-11-28),

11. 5384412 - Saccharide intermediates in the formation of the calicheamicin and (1995-01-24),

12. 5281710 - Dynemicin analogs: synthesis, methods of preparation and use (1994-01-25),

13. 5276159 - Dynemicin analogs: syntheses, methods of preparation and use (1994-01-04),

Title: Wilhelm Stahl: Innovator in Antifungal Research

Introduction

Wilhelm Stahl is a prominent inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of antifungal research, holding a total of 13 patents. His innovative work focuses on the development of processes and methods that enhance the understanding and application of antifungal peptides.

Latest Patents

Stahl's latest patents include groundbreaking inventions such as antifungal peptides derived from *Scleroderma texense*. He has also developed in-vitro transcription processes for screening natural products and other chemical substances. One notable process he invented involves analyzing transcription in a manner that can be automated and is suitable for bulk screening. This process entails transcribing a DNA sequence using a nuclear extract, which can be complemented or fully replaced by exogenous transcription factors and/or cofactors. The method includes optional steps for removing proteins from the reaction mixture, binding the resulting transcript to a solid matrix, and determining the amount of labeled transcript. His methods are designed to identify compounds that have a selective effect on gene expression.

Career Highlights

Throughout his career, Wilhelm Stahl has worked with notable organizations, including Hoechst Aktiengesellschaft and The Scripps Research Institute. His work in these institutions has allowed him to advance his research and contribute to the scientific community significantly.

Collaborations

Stahl has collaborated with esteemed colleagues such as Kyriacos Costa Nicolaou and Erwin Paul Schreiner. These partnerships have further enriched his research and innovation in the field.

Conclusion

Wilhelm Stahl's contributions to antifungal research and his innovative patents highlight his role as a leading inventor in the scientific community. His work continues to influence the development of new methods and compounds in the field of gene expression and antifungal treatments.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com